Loading…

Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist

Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie International Edition 2023-11, Vol.62 (48), p.e202312897-n/a
Main Authors: Lv, Mengdi, Zheng, Yue, Wu, Jian, Shen, Zhengqi, Guo, Binglian, Hu, Guojing, Huang, Yuanlei, Zhao, Jingyue, Qian, Yong, Su, Zhi, Wu, Chao, Xue, Xuling, Liu, Hong‐Ke, Mao, Zong‐Wan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13
cites cdi_FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13
container_end_page n/a
container_issue 48
container_start_page e202312897
container_title Angewandte Chemie International Edition
container_volume 62
creator Lv, Mengdi
Zheng, Yue
Wu, Jian
Shen, Zhengqi
Guo, Binglian
Hu, Guojing
Huang, Yuanlei
Zhao, Jingyue
Qian, Yong
Su, Zhi
Wu, Chao
Xue, Xuling
Liu, Hong‐Ke
Mao, Zong‐Wan
description Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic enhancement (MLSE) strategy involving the reaction of [Ir(Cp*)Cl]2Cl2 with the natural product Betulin. The fusion of Betulin with iridium cyclopentadienyl (Ir‐Cp*) species as Ir‐Bet not only tremendously enhanced the antiproliferative activity toward cancer cells, but also activated ferritinophagy for iron homeostasis regulation by PI3K/Akt/mTOR cascade inhibition with a lower dosage of Betulin, and then evoked an immune response by nuclear factor kappa‐B (NF‐κB) activation of Ir‐Cp* species. Further immunogenic cell death (ICD) occurred by remarkable ferroptosis through glutathione (GSH) depletion, glutathione peroxidase 4 (GPX4) deactivation and ferritinophagy. An in vivo vaccination experiment demonstrated desirable antitumor and immunogenic effects of Ir‐Bet by increasing the ratio of cytotoxic T cells (CTLs)/regulatory T cells (Tregs). A metal‐ligand synergistic enhancement (MLSE) strategy was used to develop an immune agonist Ir‐Bet composed of an iridium complex fused with the natural product Betulin, which induced ferritinophagy‐enhanced ferroptosis to activate antitumor immunity. The MLSE strategy not only promotes effective ferroptosis and immunogenic cell death (ICD), but also provides a new mechanism of action for metal‐based anticancer complexes for cancer therapy.
doi_str_mv 10.1002/anie.202312897
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2877388932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2877388932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13</originalsourceid><addsrcrecordid>eNqFkU1P3DAQhq0KVD7aa4_IEpdesvgjiZ3jdrVLV0JwoD1Hjj3ZGhJ7aydUufET-hv5JfVqKUhcOM2M9Myj0bwIfaFkRglhF8pZmDHCOGWyEh_QMS0YzbgQ_CD1OeeZkAU9Qicx3iVeSlJ-REdcSE6ooMcIlg_-3roNXkEIfjv4aCNuJnw7OQgbGwer8dL9Uk5DD27AvsUKLybd-W0albHgpg6vgzV27J8e_36DYeysw-u-Hx3g-ca7JPmEDlvVRfj8XE_Rz9Xyx-J7dnVzuV7MrzKdUy6ylgtTNkTlVbquyQvJdEkNaSsC0kgwpWlUaaQw0nBNSlaRnOaMcC0KzShQfoq-7r3b4H-PEIe6t1FD1ykHfow1k-kxUlacJfT8DXrnx-DSdYmqaFXwQuyEsz2lg48xQFtvg-1VmGpK6l0A9S6A-iWAtHD2rB2bHswL_v_jCaj2wB_bwfSOrp5fr5ev8n87BZMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2891953571</pqid></control><display><type>article</type><title>Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist</title><source>Wiley</source><creator>Lv, Mengdi ; Zheng, Yue ; Wu, Jian ; Shen, Zhengqi ; Guo, Binglian ; Hu, Guojing ; Huang, Yuanlei ; Zhao, Jingyue ; Qian, Yong ; Su, Zhi ; Wu, Chao ; Xue, Xuling ; Liu, Hong‐Ke ; Mao, Zong‐Wan</creator><creatorcontrib>Lv, Mengdi ; Zheng, Yue ; Wu, Jian ; Shen, Zhengqi ; Guo, Binglian ; Hu, Guojing ; Huang, Yuanlei ; Zhao, Jingyue ; Qian, Yong ; Su, Zhi ; Wu, Chao ; Xue, Xuling ; Liu, Hong‐Ke ; Mao, Zong‐Wan</creatorcontrib><description>Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic enhancement (MLSE) strategy involving the reaction of [Ir(Cp*)Cl]2Cl2 with the natural product Betulin. The fusion of Betulin with iridium cyclopentadienyl (Ir‐Cp*) species as Ir‐Bet not only tremendously enhanced the antiproliferative activity toward cancer cells, but also activated ferritinophagy for iron homeostasis regulation by PI3K/Akt/mTOR cascade inhibition with a lower dosage of Betulin, and then evoked an immune response by nuclear factor kappa‐B (NF‐κB) activation of Ir‐Cp* species. Further immunogenic cell death (ICD) occurred by remarkable ferroptosis through glutathione (GSH) depletion, glutathione peroxidase 4 (GPX4) deactivation and ferritinophagy. An in vivo vaccination experiment demonstrated desirable antitumor and immunogenic effects of Ir‐Bet by increasing the ratio of cytotoxic T cells (CTLs)/regulatory T cells (Tregs). A metal‐ligand synergistic enhancement (MLSE) strategy was used to develop an immune agonist Ir‐Bet composed of an iridium complex fused with the natural product Betulin, which induced ferritinophagy‐enhanced ferroptosis to activate antitumor immunity. The MLSE strategy not only promotes effective ferroptosis and immunogenic cell death (ICD), but also provides a new mechanism of action for metal‐based anticancer complexes for cancer therapy.</description><edition>International ed. in English</edition><identifier>ISSN: 1433-7851</identifier><identifier>EISSN: 1521-3773</identifier><identifier>DOI: 10.1002/anie.202312897</identifier><identifier>PMID: 37830171</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>1-Phosphatidylinositol 3-kinase ; AKT protein ; Anticancer properties ; Antitumor activity ; Apoptosis ; Cell death ; Cyclopentadienyl Ligands ; Cytotoxicity ; Ferroptosis ; Glutathione ; Glutathione peroxidase ; Homeostasis ; Immune response ; Immune system ; Immunochemotherapy ; Immunogenicity ; Immunoregulation ; Iridium ; Iridium - pharmacology ; Iridium Complexes ; Iron ; Iron - metabolism ; Lipid peroxidation ; Lipids ; Lymphocytes ; Lymphocytes T ; Natural products ; Nonferrous metals ; Peroxidase ; Peroxidation ; Phosphatidylinositol 3-Kinases ; Synergistic Strategy ; TOR protein ; Vaccination</subject><ispartof>Angewandte Chemie International Edition, 2023-11, Vol.62 (48), p.e202312897-n/a</ispartof><rights>2023 Wiley‐VCH GmbH</rights><rights>2023 Wiley-VCH GmbH.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13</citedby><cites>FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13</cites><orcidid>0000-0003-4720-7378 ; 0000-0002-0968-6518 ; 0000-0001-7131-1154</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37830171$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lv, Mengdi</creatorcontrib><creatorcontrib>Zheng, Yue</creatorcontrib><creatorcontrib>Wu, Jian</creatorcontrib><creatorcontrib>Shen, Zhengqi</creatorcontrib><creatorcontrib>Guo, Binglian</creatorcontrib><creatorcontrib>Hu, Guojing</creatorcontrib><creatorcontrib>Huang, Yuanlei</creatorcontrib><creatorcontrib>Zhao, Jingyue</creatorcontrib><creatorcontrib>Qian, Yong</creatorcontrib><creatorcontrib>Su, Zhi</creatorcontrib><creatorcontrib>Wu, Chao</creatorcontrib><creatorcontrib>Xue, Xuling</creatorcontrib><creatorcontrib>Liu, Hong‐Ke</creatorcontrib><creatorcontrib>Mao, Zong‐Wan</creatorcontrib><title>Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist</title><title>Angewandte Chemie International Edition</title><addtitle>Angew Chem Int Ed Engl</addtitle><description>Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic enhancement (MLSE) strategy involving the reaction of [Ir(Cp*)Cl]2Cl2 with the natural product Betulin. The fusion of Betulin with iridium cyclopentadienyl (Ir‐Cp*) species as Ir‐Bet not only tremendously enhanced the antiproliferative activity toward cancer cells, but also activated ferritinophagy for iron homeostasis regulation by PI3K/Akt/mTOR cascade inhibition with a lower dosage of Betulin, and then evoked an immune response by nuclear factor kappa‐B (NF‐κB) activation of Ir‐Cp* species. Further immunogenic cell death (ICD) occurred by remarkable ferroptosis through glutathione (GSH) depletion, glutathione peroxidase 4 (GPX4) deactivation and ferritinophagy. An in vivo vaccination experiment demonstrated desirable antitumor and immunogenic effects of Ir‐Bet by increasing the ratio of cytotoxic T cells (CTLs)/regulatory T cells (Tregs). A metal‐ligand synergistic enhancement (MLSE) strategy was used to develop an immune agonist Ir‐Bet composed of an iridium complex fused with the natural product Betulin, which induced ferritinophagy‐enhanced ferroptosis to activate antitumor immunity. The MLSE strategy not only promotes effective ferroptosis and immunogenic cell death (ICD), but also provides a new mechanism of action for metal‐based anticancer complexes for cancer therapy.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>AKT protein</subject><subject>Anticancer properties</subject><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>Cell death</subject><subject>Cyclopentadienyl Ligands</subject><subject>Cytotoxicity</subject><subject>Ferroptosis</subject><subject>Glutathione</subject><subject>Glutathione peroxidase</subject><subject>Homeostasis</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunochemotherapy</subject><subject>Immunogenicity</subject><subject>Immunoregulation</subject><subject>Iridium</subject><subject>Iridium - pharmacology</subject><subject>Iridium Complexes</subject><subject>Iron</subject><subject>Iron - metabolism</subject><subject>Lipid peroxidation</subject><subject>Lipids</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Natural products</subject><subject>Nonferrous metals</subject><subject>Peroxidase</subject><subject>Peroxidation</subject><subject>Phosphatidylinositol 3-Kinases</subject><subject>Synergistic Strategy</subject><subject>TOR protein</subject><subject>Vaccination</subject><issn>1433-7851</issn><issn>1521-3773</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkU1P3DAQhq0KVD7aa4_IEpdesvgjiZ3jdrVLV0JwoD1Hjj3ZGhJ7aydUufET-hv5JfVqKUhcOM2M9Myj0bwIfaFkRglhF8pZmDHCOGWyEh_QMS0YzbgQ_CD1OeeZkAU9Qicx3iVeSlJ-REdcSE6ooMcIlg_-3roNXkEIfjv4aCNuJnw7OQgbGwer8dL9Uk5DD27AvsUKLybd-W0albHgpg6vgzV27J8e_36DYeysw-u-Hx3g-ca7JPmEDlvVRfj8XE_Rz9Xyx-J7dnVzuV7MrzKdUy6ylgtTNkTlVbquyQvJdEkNaSsC0kgwpWlUaaQw0nBNSlaRnOaMcC0KzShQfoq-7r3b4H-PEIe6t1FD1ykHfow1k-kxUlacJfT8DXrnx-DSdYmqaFXwQuyEsz2lg48xQFtvg-1VmGpK6l0A9S6A-iWAtHD2rB2bHswL_v_jCaj2wB_bwfSOrp5fr5ev8n87BZMg</recordid><startdate>20231127</startdate><enddate>20231127</enddate><creator>Lv, Mengdi</creator><creator>Zheng, Yue</creator><creator>Wu, Jian</creator><creator>Shen, Zhengqi</creator><creator>Guo, Binglian</creator><creator>Hu, Guojing</creator><creator>Huang, Yuanlei</creator><creator>Zhao, Jingyue</creator><creator>Qian, Yong</creator><creator>Su, Zhi</creator><creator>Wu, Chao</creator><creator>Xue, Xuling</creator><creator>Liu, Hong‐Ke</creator><creator>Mao, Zong‐Wan</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4720-7378</orcidid><orcidid>https://orcid.org/0000-0002-0968-6518</orcidid><orcidid>https://orcid.org/0000-0001-7131-1154</orcidid></search><sort><creationdate>20231127</creationdate><title>Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist</title><author>Lv, Mengdi ; Zheng, Yue ; Wu, Jian ; Shen, Zhengqi ; Guo, Binglian ; Hu, Guojing ; Huang, Yuanlei ; Zhao, Jingyue ; Qian, Yong ; Su, Zhi ; Wu, Chao ; Xue, Xuling ; Liu, Hong‐Ke ; Mao, Zong‐Wan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>AKT protein</topic><topic>Anticancer properties</topic><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>Cell death</topic><topic>Cyclopentadienyl Ligands</topic><topic>Cytotoxicity</topic><topic>Ferroptosis</topic><topic>Glutathione</topic><topic>Glutathione peroxidase</topic><topic>Homeostasis</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunochemotherapy</topic><topic>Immunogenicity</topic><topic>Immunoregulation</topic><topic>Iridium</topic><topic>Iridium - pharmacology</topic><topic>Iridium Complexes</topic><topic>Iron</topic><topic>Iron - metabolism</topic><topic>Lipid peroxidation</topic><topic>Lipids</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Natural products</topic><topic>Nonferrous metals</topic><topic>Peroxidase</topic><topic>Peroxidation</topic><topic>Phosphatidylinositol 3-Kinases</topic><topic>Synergistic Strategy</topic><topic>TOR protein</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lv, Mengdi</creatorcontrib><creatorcontrib>Zheng, Yue</creatorcontrib><creatorcontrib>Wu, Jian</creatorcontrib><creatorcontrib>Shen, Zhengqi</creatorcontrib><creatorcontrib>Guo, Binglian</creatorcontrib><creatorcontrib>Hu, Guojing</creatorcontrib><creatorcontrib>Huang, Yuanlei</creatorcontrib><creatorcontrib>Zhao, Jingyue</creatorcontrib><creatorcontrib>Qian, Yong</creatorcontrib><creatorcontrib>Su, Zhi</creatorcontrib><creatorcontrib>Wu, Chao</creatorcontrib><creatorcontrib>Xue, Xuling</creatorcontrib><creatorcontrib>Liu, Hong‐Ke</creatorcontrib><creatorcontrib>Mao, Zong‐Wan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Angewandte Chemie International Edition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lv, Mengdi</au><au>Zheng, Yue</au><au>Wu, Jian</au><au>Shen, Zhengqi</au><au>Guo, Binglian</au><au>Hu, Guojing</au><au>Huang, Yuanlei</au><au>Zhao, Jingyue</au><au>Qian, Yong</au><au>Su, Zhi</au><au>Wu, Chao</au><au>Xue, Xuling</au><au>Liu, Hong‐Ke</au><au>Mao, Zong‐Wan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist</atitle><jtitle>Angewandte Chemie International Edition</jtitle><addtitle>Angew Chem Int Ed Engl</addtitle><date>2023-11-27</date><risdate>2023</risdate><volume>62</volume><issue>48</issue><spage>e202312897</spage><epage>n/a</epage><pages>e202312897-n/a</pages><issn>1433-7851</issn><eissn>1521-3773</eissn><abstract>Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic enhancement (MLSE) strategy involving the reaction of [Ir(Cp*)Cl]2Cl2 with the natural product Betulin. The fusion of Betulin with iridium cyclopentadienyl (Ir‐Cp*) species as Ir‐Bet not only tremendously enhanced the antiproliferative activity toward cancer cells, but also activated ferritinophagy for iron homeostasis regulation by PI3K/Akt/mTOR cascade inhibition with a lower dosage of Betulin, and then evoked an immune response by nuclear factor kappa‐B (NF‐κB) activation of Ir‐Cp* species. Further immunogenic cell death (ICD) occurred by remarkable ferroptosis through glutathione (GSH) depletion, glutathione peroxidase 4 (GPX4) deactivation and ferritinophagy. An in vivo vaccination experiment demonstrated desirable antitumor and immunogenic effects of Ir‐Bet by increasing the ratio of cytotoxic T cells (CTLs)/regulatory T cells (Tregs). A metal‐ligand synergistic enhancement (MLSE) strategy was used to develop an immune agonist Ir‐Bet composed of an iridium complex fused with the natural product Betulin, which induced ferritinophagy‐enhanced ferroptosis to activate antitumor immunity. The MLSE strategy not only promotes effective ferroptosis and immunogenic cell death (ICD), but also provides a new mechanism of action for metal‐based anticancer complexes for cancer therapy.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37830171</pmid><doi>10.1002/anie.202312897</doi><tpages>12</tpages><edition>International ed. in English</edition><orcidid>https://orcid.org/0000-0003-4720-7378</orcidid><orcidid>https://orcid.org/0000-0002-0968-6518</orcidid><orcidid>https://orcid.org/0000-0001-7131-1154</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1433-7851
ispartof Angewandte Chemie International Edition, 2023-11, Vol.62 (48), p.e202312897-n/a
issn 1433-7851
1521-3773
language eng
recordid cdi_proquest_miscellaneous_2877388932
source Wiley
subjects 1-Phosphatidylinositol 3-kinase
AKT protein
Anticancer properties
Antitumor activity
Apoptosis
Cell death
Cyclopentadienyl Ligands
Cytotoxicity
Ferroptosis
Glutathione
Glutathione peroxidase
Homeostasis
Immune response
Immune system
Immunochemotherapy
Immunogenicity
Immunoregulation
Iridium
Iridium - pharmacology
Iridium Complexes
Iron
Iron - metabolism
Lipid peroxidation
Lipids
Lymphocytes
Lymphocytes T
Natural products
Nonferrous metals
Peroxidase
Peroxidation
Phosphatidylinositol 3-Kinases
Synergistic Strategy
TOR protein
Vaccination
title Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evoking%20Ferroptosis%20by%20Synergistic%20Enhancement%20of%20a%20Cyclopentadienyl%20Iridium%E2%80%90Betulin%20Immune%20Agonist&rft.jtitle=Angewandte%20Chemie%20International%20Edition&rft.au=Lv,%20Mengdi&rft.date=2023-11-27&rft.volume=62&rft.issue=48&rft.spage=e202312897&rft.epage=n/a&rft.pages=e202312897-n/a&rft.issn=1433-7851&rft.eissn=1521-3773&rft_id=info:doi/10.1002/anie.202312897&rft_dat=%3Cproquest_cross%3E2877388932%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2891953571&rft_id=info:pmid/37830171&rfr_iscdi=true